Latest Administration News

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

Xero Limited has agreed to acquire Melio Limited, a leading US SMB bill pay platform, for US$2.5 billion, marking a significant leap in its US growth strategy. The deal is backed by a substantial A$1.85 billion equity raise and aims to accelerate revenue and market presence by FY28.

Cyprium Metals has obtained crucial environmental and operational approvals to advance the phased redevelopment of its Nifty Copper Complex, setting the stage for a near-term production restart.

Zeotech Limited’s Preliminary Feasibility Study (PFS) for its AusPozz™ Project reveals a robust business case for Australia’s first metakaolin production facility, promising strong financial returns and significant carbon emission reductions.

eMetals Limited reveals a significant 300-meter-wide gold-in-soil anomaly at its Busia Gold Project in Uganda, highlighting promising early exploration results within a highly prospective greenstone belt.

Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.

Virgin Australia Holdings Limited is set to list on the ASX, raising $685 million through a mix of new and existing shares, showcasing its transformation journey and strategic partnership with Qatar Airways.

Ronin Resources Limited updates ASX on delayed exploration activities and relinquished projects, citing socio-political challenges and market conditions. The company anticipates key licence grants by August 2025 and confirms compliance with listing rules while seeking new opportunities.

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

ENRG Elements Limited has confirmed the materiality of recent director resignations and appointments, clarifying timing and compliance with ASX disclosure rules.